A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Phase 3, multizentrische, randomisierte klinische Open-Label-Studie von GSK5764227, einem B7-H3-Antikörper-Arzneimittelkonjugat (ADC), im Vergleich zu Topotecan bei Teilnehmern mit rezidiviertem kleinem Zell-Lungenkrebs (SCLC)
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
Studieren Sie die Kontaktsicherung
- Name: EU GSK Clinical Trials Call Center
- Telefonnummer: +44 (0) 20 89904466
- E-Mail: GSKClinicalSupportHD@gsk.com
Studienorte
-
-
-
Buenos Aires, Argentinien, C1426ABP
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Christian Fuentes
-
Ciudad Autonoma de Buenos Aire, Argentinien, C1012AAR
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Pedro Martin Paskevicius
-
Ciudad Autonoma de Buenos Aire, Argentinien, C1426AGE
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Nicolas Minatta
-
Rosario, Argentinien, S2000 DEJ
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Gabriel Garbaos
-
Vicente López, Argentinien, 1602
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Gustavo Lopez
-
-
Buenos Aires
-
Mar del Plata, Buenos Aires, Argentinien, 7600
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ignacio Casarini
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Australien, 2148
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Emma Boys
-
St Leonards, New South Wales, Australien, 2065
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Malinda Itchins
-
-
Victoria
-
Melbourne, Victoria, Australien, 3000
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Benjamin Solomon
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Zurückgezogen
- GSK Investigational Site
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Flavio Augusto Ferreira da Silva
-
CuritibaPR, Brasilien, 80810-050
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Karina Costa Maia Vianna
-
Porto Alegre, Brasilien, 90610-000
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ana Gelatti
-
Porto Alegre, Brasilien, 90020-090
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Katsuki Tiscoski
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Rio de Janeiro, Brasilien, 22250-905
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Tatiane Montella
-
São Paulo, Brasilien, 04312903
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Gilberto De Castro Junior
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- fabricio grando
-
-
-
-
-
Pleven, Bulgarien, 5800
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yordan Ignatov
-
Plovdiv, Bulgarien
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Vladimir Kanarev
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Rousse, Bulgarien, 7002
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Nikolay Nikolaev
-
Sofia, Bulgarien, 1606
- Zurückgezogen
- GSK Investigational Site
-
Sofia, Bulgarien, 1303
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Krasimir Koynov
-
-
-
-
-
Augsburg, Deutschland, 86156
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Bjoern Hackanson
-
Chemnitz, Deutschland, 09113
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Stefan Hammerschmidt
-
Esslingen am Neckar, Deutschland, 73730
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Martin Faehling
-
Heidelberg, Deutschland, 69126
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Johannes Schnorbach
-
Immenhausen, Deutschland, 34376
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Achim Rittmeyer
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Lübeck, Deutschland, 23562
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Jens Kisro
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
München, Deutschland, 81377
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Diego Kauffmann-Guerrero
-
Nuremberg, Deutschland, 90340
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Markus Horneber
-
Regensburg, Deutschland, 93053
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Christian Schulz
-
-
Baden-Wurttemberg
-
Karlsruhe, Baden-Wurttemberg, Deutschland, 76137
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Christian Meyer zum Bueschenfelde
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Löwenstein, Baden-Wurttemberg, Deutschland, 74245
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Jonas Kuon
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Stuttgart, Baden-Wurttemberg, Deutschland, 70376
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Perihan Canoglu
-
-
-
-
-
Vaasa, Finnland, 65130
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ravichandra Ravi
-
-
-
-
-
Boulogne-Billancourt, Frankreich, 92100
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Etienne Giroux Leprieur
-
Grenoble, Frankreich, 38043
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Denis Moro-Sibilot
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Saint-Herblain, Frankreich, 44805
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Sandrine Hiret
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Villejuif, Frankreich, 94805
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Pernelle Lavaud
-
-
-
-
-
Athens, Griechenland, 12462
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Amanda Psyrri
-
Athens, Griechenland, 115 22
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- ANASTASIOS GRIVAS
-
Pylaia Thessaloniki, Griechenland, 57001
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Ippokratis Korantzis
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Pylaia Thessaloniki, Griechenland, 570 01
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Sofia Baka
-
-
Attica
-
Athens, Attica, Griechenland, 115 26
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ioannis Mountzios
-
-
Crete
-
Heraklion, Crete, Griechenland, 700 13
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Sofia Agelaki
-
-
-
-
-
Dublin, Irland, D09 V2N0
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Jarushka Naidoo
-
-
-
-
-
Jerusalem, Israel, 9112001
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yakir Rottenberg
-
Tel Aviv, Israel, 6423906
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- ido wolf
-
-
-
-
-
Bergamo, Italien
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Chiara Catania
-
Genova, Italien, 16132
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Francesco Grossi
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Orbassano, Italien, 10043
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Francesco Passiglia
-
Pisa, Italien, 57124
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Giacomo Allegrini
-
Siena, Italien, 53100
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Michele Maio
-
Verona, Italien, 37134
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Jessica Menis
-
-
MI
-
Milan, MI, Italien, 20141
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Antonio Passaro
-
-
RM
-
Roma, RM, Italien, 00168
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Emilio Bria
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Fukuoka, Japan, 812-8582
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Isamu Okamoto
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hokkaido, Japan, 060-8648
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yasuyuki Ikezawa
-
Ishikawa, Japan, 920-8530
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Takashi Sone
-
Kagoshima, Japan, 890-8520
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Shunsuke Misono
-
Kanagawa, Japan, 241-8515
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Shuji Murakami
-
Kanagawa, Japan, 252-0375
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Katsuhiko Naoki
-
Kochi, Japan, 783-8505
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Toshiyuki Kozuki
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kyoto, Japan, 612-8555
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Kohei Fujita
-
Mie, Japan, 515-8544
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Osamu Hataji
-
Miyagi, Japan, 980-8574
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Eisaku Miyauchi
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Osaka, Japan, 541-8567
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- takako inoue
-
Osaka, Japan, 573-1191
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Takayasu Kurata
-
Osaka, Japan, 594-0073
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Takafumi Okabe
-
Tokyo, Japan, 113-8603
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Kazuo Kasahara
-
Tokyo, Japan, 104-0045
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yasushi Goto
-
Tokyo, Japan, 113-8677
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yukio Hosomi
-
Toyama, Japan, 930-8550
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Hirokazu Taniguchi
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8L6
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Paul Wheatley-Price
-
Toronto, Ontario, Kanada, M5G 1Z5
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Natasha Leighl
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Jennifer Friedmann
-
Montreal, Quebec, Kanada, H4J 1C5
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Kevin Jao
-
-
-
-
-
Guadajalara, Mexiko, 44280
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Juan Carlos Vazquez Limon
-
Mexico City, Mexiko, 06760
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Raul Rogelio Trejo-Rosales
-
Mexico City, Mexiko, 06700
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Eleazar Omar Macedo-Perez
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
Nuevo León
-
San Pedro Garza García, Nuevo León, Mexiko, 66260
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Hector Marcelino Diaz-Perez
-
-
-
-
-
Gliwice, Polen, 44-102
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Grzegorz Slomian
-
Kielce, Polen, 25-640
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Tomasz Kucharczyk
-
Lodz, Polen, 93-338
- Zurückgezogen
- GSK Investigational Site
-
Olsztyn, Polen, 10-357
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Jarosław Kołb-Sielecki
-
Otwock, Polen, 05-400
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Aleksandra Szczesna
-
Poznan, Polen, 60-569
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Katarzyna Stencel
-
Przemyśl, Polen, 37-700
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Kamil Kuc
-
Siedlce, Polen, 08-110
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Lubomir Bodnar
-
-
-
-
-
Coimbra, Portugal, 3000-075
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Sara Póvoa
-
Guimarães, Portugal, 4835-044
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Pedro Brito
-
Lisbon, Portugal, 1400-038
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Patrícia Garrido
-
-
Setúbal District
-
Almada, Setúbal District, Portugal, 2805-267
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Miguel Lopes
-
-
-
-
-
Cluj-Napoca, Rumänien, 400015
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Cristina Ligia Cebotaru
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Craiova, Rumänien, 200542
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Michael Schenker
-
Floreşti, Rumänien, 407280
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Andrei Ungureanu
-
Iași, Rumänien, 700451
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Teodora Alexa Stratulat
-
Timișoara, Rumänien, 300329
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- DANIELA SIRBU
-
-
Dolj
-
Craiova Dolj, Dolj, Rumänien, 200535
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Cristian Lungulescu
-
-
-
-
-
Stockholm, Schweden, 171 64
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Hannah Björn Andtback
-
-
-
-
-
Basel, Schweiz, 4031
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Andreas Schmitt
-
Lausanne, Schweiz, 1011
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Nuria Neisy Mederos Alfonso
-
-
-
-
-
Barcelona, Spanien, 08003
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Edurne Arriola Aperribay
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Barcelona, Spanien, 08035
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Pedro Rocha
-
Barcelona, Spanien, 8036
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Noemi Reguart Aransay
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
L'Hospitalet de Llobrega, Spanien, 08908
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Miguel Ángel Mosteiro Lamas
-
Las Palmas de Gran Canar, Spanien, 35016
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Delvys Rodriguez-Abreu
-
Madrid, Spanien, 28046
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Javier Francisco De Castro Carpeño
-
Madrid, Spanien, 28034
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- María Eugenia Olmedo García
-
Madrid, Spanien, 28041
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Luis Paz-Ares
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Madrid, Spanien, 28007
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Rosa Alvarez Alvarez
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Santander, Spanien, 39011
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Marta Lopez-Brea Piqueras
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Changwon, Südkorea, 51472
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Junho Ji
-
Cheongju Chungcheongbuk-do, Südkorea, 28644
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Ki Hyeong Lee
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Daegu, Südkorea, 41404
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Seung Soo Yoo
-
Gyeonggi-do, Südkorea, 10408
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Beung Chul Ahn
-
Seongnam-si Gyeonggi-do, Südkorea, 13620
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Yu Jung Kim
-
Seoul, Südkorea, 03722
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Hye Ryun Kim
-
Suwon Gyeonggi-do, Südkorea, 442723
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Byoung Yong Shim
-
Ulsan, Südkorea, 44033
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Cheol Kyung Sin
-
-
-
-
-
Ankara, Türkei (türkiye), 06010
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ismail Erturk
-
Ankara, Türkei (türkiye), 06520
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Umut Demirci
-
Ankara, Türkei (türkiye), 6230
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Mustafa Erman
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Diyarbakır, Türkei (türkiye), 21280
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Muhammet Kaplan
-
Istanbul, Türkei (türkiye), 34010
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Seyda Gunduz
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Izmir, Türkei (türkiye), 35110
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Sema Erturk
-
Izmir, Türkei (türkiye), 35340
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Elif Atag
-
-
Adana
-
Adana, Adana, Türkei (türkiye), 01140
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ahmet Sumbul
-
-
Atakum
-
Samsun, Atakum, Türkei (türkiye), 55200
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Dilek Erdem
-
-
-
-
-
Budapest, Ungarn, H-1121
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Gabriella Temesi
-
Farkasgyepű, Ungarn, 8552
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Zsolt Király
-
Gyöngyös, Ungarn, 3200
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- István Albert
-
Kecskemét, Ungarn, 6000
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Zsuzsanna Kelemen
-
Székesfehérvár, Ungarn, 8000
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Zsolt Pápai Székely
-
Törökbálint, Ungarn, 2045
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Gabriella Gálffy
-
-
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90027
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Ghassan Al-Jazayrly
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
-
Florida
-
Hialeah, Florida, Vereinigte Staaten, 33013
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Luis Rangel
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Francisco Belette
-
Plantation, Florida, Vereinigte Staaten, 33322-5426
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Jason Tache
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Tamarac, Florida, Vereinigte Staaten, 33321
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Andrew Schneider
-
-
Illinois
-
Hinsdale, Illinois, Vereinigte Staaten, 60521
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Srilata Gundala
-
-
New York
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Ajeet Gajra
-
-
North Carolina
-
Wilson, North Carolina, Vereinigte Staaten, 27893-3484
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Keith Lerro
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten, 44718
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Nashat Gabrail
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Latha Neerukonda
-
-
-
-
-
London, Vereinigtes Königreich, W1G 6AD
- Rekrutierung
- GSK Investigational Site
-
Hauptermittler:
- Anja Williams
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Portsmouth, Vereinigtes Königreich, PO6 3LY
- Zurückgezogen
- GSK Investigational Site
-
Truro, Vereinigtes Königreich, TR1 3LJ
- Rekrutierung
- GSK Investigational Site
-
Kontakt:
- US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Kontakt:
- EU GSK Clinical Trials Call Centre
- Telefonnummer: +44 (0) 20 8990 4466
- E-Mail: GSKClinicalSupportHD@gsk.com
-
Hauptermittler:
- Grant Stewart
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
- Adults >18 or the minimum legal adult age at the time the informed consent form is signed
- Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
- Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible.
- Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
- Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
- Has adequate organ function and an ECOG performance status of 0 or 1
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Pathological diagnosis of complex SCLC or transformed SCLC.
- Limited stage small cell lung cancer at diagnosis
- Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3.
- Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
- Has severe, uncontrolled or active cardiovascular disorders.
- Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
- Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
- Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases.
- Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids.
- Has significant pulmonary disease or respiratory impairment (e.g., uncontrolled asthma/COPD, restrictive lung disease),
- Has active Hepatitis B or Hepatitis C
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Topotecan
|
Topotecan will be administered |
|
Experimental: Risvutatug rezetecan (Ris-Rez)
|
Ris-Rez will be administered |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival (OS)
Zeitfenster: Up to approximately 113 weeks
|
OS is defined as the time from the date of randomization to the date of death by any cause |
Up to approximately 113 weeks
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Teilnehmer mit unerwünschten Ereignissen (UE), schwerwiegenden unerwünschten Ereignissen (SUE) und unerwünschten Ereignissen von besonderem Interesse (UEBI) nach Schweregrad
Zeitfenster: Bis zu etwa 139 Wochen
|
Bis zu etwa 139 Wochen
|
|
|
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Zeitfenster: Up to approximately 139 weeks
|
Up to approximately 139 weeks
|
|
|
Beobachtete PK-Konzentrationen von Ris-Rez (konjugiertem Antikörper und niedermolekularer Fracht)
Zeitfenster: Bis zu circa 139 Wochen
|
Bis zu circa 139 Wochen
|
|
|
Anzahl der Teilnehmer mit Antidrug-Antikörpern (ADA) oder neutralisierenden Antikörpern (NAb)
Zeitfenster: Bis zu etwa 139 Wochen
|
Bis zu etwa 139 Wochen
|
|
|
ADA-Titer gegen Ris-Rez
Zeitfenster: Bis zu etwa 139 Wochen
|
Bis zu etwa 139 Wochen
|
|
|
Brain PFS
Zeitfenster: Up to approximately 139 weeks
|
Brain PFS is defined as the time from the date of randomization to the date of first documented PD per modified Response assessment in neuro-oncology (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with history of brain metastasis or presence of brain metastasis at baseline |
Up to approximately 139 weeks
|
|
Change from baseline in cough
Zeitfenster: Up to approximately 18 weeks
|
Validated questionnaires will be used for the assessment |
Up to approximately 18 weeks
|
|
Change from baseline in dyspnea
Zeitfenster: Up to approximately 18 weeks
|
Validated questionnaires will be used for the assessment |
Up to approximately 18 weeks
|
|
Change from baseline in chest pain
Zeitfenster: Up to approximately 18 weeks
|
Validated questionnaires will be used for the assessment |
Up to approximately 18 weeks
|
|
Time to clinical deterioration in physical functioning
Zeitfenster: Up to approximately 139 weeks
|
Time to clinical deterioration in physical functioning will be measured using validated questionnaires |
Up to approximately 139 weeks
|
|
Objective Response Rate (ORR)
Zeitfenster: Up to approximately 139 weeks
|
ORR is defined as the percentage of participants with a confirmed complete (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator/Blinded Independent Central Review (BICR) assessment |
Up to approximately 139 weeks
|
|
Duration of Response (DoR)
Zeitfenster: Up to approximately 139 weeks
|
DoR is defined as the time from the date of first documented objective response (CR or PR) per RECIST 1.1 by investigator/BICR assessment to the date of first documented PD per RECIST 1.1 by investigator/BICR assessment or death due to any cause, whichever comes first |
Up to approximately 139 weeks
|
|
Progression-free survival (PFS)
Zeitfenster: Up to approximately 139 weeks
|
PFS is defined as the time from the date of randomization to the date of first documented Progressive disease (PD) per RECIST 1.1 by investigator/BICR assessment or death from any cause, whichever occurs first |
Up to approximately 139 weeks
|
|
Disease control rate (DCR) 12
Zeitfenster: Up to approximately 11 weeks
|
DCR12 is defined as the percentage of participants who have a Best objective response (BOR) of confirmed CR, confirmed PR, or Stable Disease (SD) for a duration of at least 11 weeks, per RECIST 1.1 by investigator/BICR assessment |
Up to approximately 11 weeks
|
|
Brain DoR
Zeitfenster: Up to approximately 139 weeks
|
Brain DoR is defined as the time from the first documented objective response (CR/PR according to modified RANO-BM BICR assessment) until the time of first documentation of disease progression or death, whichever occurs first, in participants with a history of brain metastasis or presence of brain metastasis at baseline |
Up to approximately 139 weeks
|
|
Brain ORR
Zeitfenster: Up to approximately 139 weeks
|
Brain ORR is defined as the percentage of participants with confirmed brain CR or confirmed brain PR per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline |
Up to approximately 139 weeks
|
|
Brain DCR12
Zeitfenster: Up to approximately 11 weeks
|
Brain DCR12 is defined as the percentage of participants with an intracranial BOR of confirmed CR, confirmed PR or SD after the date of randomization, per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline |
Up to approximately 11 weeks
|
|
Time to brain progression
Zeitfenster: Up to approximately 139 weeks
|
Time to brain progression is defined as the time from the date of randomization to the date of first documented brain PD per modified RANO-BM BICR assessment in participants with a history of brain metastasis or presence of brain metastasis at baseline. |
Up to approximately 139 weeks
|
|
Number of participants with a change from baseline in vital signs
Zeitfenster: Baseline (Day -1) and up to approximately 139 weeks
|
Number of participants will be assessed. |
Baseline (Day -1) and up to approximately 139 weeks
|
|
Number of participants with a change from baseline in laboratory parameters (hematology and clinical chemistry)
Zeitfenster: Baseline (Day -1) and up to approximately 139 weeks
|
Number of participants will be assessed. |
Baseline (Day -1) and up to approximately 139 weeks
|
|
Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG)
Zeitfenster: Baseline (Day -1) and up to approximately 139 weeks
|
Number of participants will be assessed. |
Baseline (Day -1) and up to approximately 139 weeks
|
|
Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Zeitfenster: Baseline (Day -1) and up to approximately 139 weeks
|
Number of participants will be assessed. |
Baseline (Day -1) and up to approximately 139 weeks
|
|
Participant reported experience with study treatment
Zeitfenster: Up to approximately 139 weeks
|
Participant reported outcomes assessing symptoms, daily functioning, and overall health status during study treatment will be measured using validated questionnaires |
Up to approximately 139 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 223674
- 2025 (US NIH Stipendium/Vertrag)
- 2025-521627-78 (Registrierungskennung: CTIS (EU))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-Sharing-Zeitrahmen
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD-Sharing-Zugriffskriterien
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .